Acadia Healthcare (NASDAQ:ACHC) Price Target Raised to $28.00 at Royal Bank Of Canada

Acadia Healthcare (NASDAQ:ACHC) had its price objective upped by research analysts at Royal Bank Of Canada from $17.00 to $28.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 27.10% from the company’s current price.

ACHC has been the subject of several other reports. KeyCorp dropped their target price on Acadia Healthcare from $30.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, December 3rd. Weiss Ratings reissued a “sell (d)” rating on shares of Acadia Healthcare in a research note on Wednesday, January 21st. Raymond James Financial set a $17.00 target price on shares of Acadia Healthcare in a research note on Wednesday, December 3rd. Cantor Fitzgerald set a $17.00 price target on shares of Acadia Healthcare in a research report on Wednesday, December 3rd. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Acadia Healthcare from $33.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, December 3rd. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $19.69.

Acadia Healthcare Price Performance

NASDAQ ACHC traded up $1.19 during trading on Thursday, reaching $22.03. The company’s stock had a trading volume of 1,584,461 shares, compared to its average volume of 3,904,702. The firm has a fifty day moving average of $14.48 and a 200 day moving average of $18.52. The stock has a market capitalization of $2.03 billion, a PE ratio of 18.92, a P/E/G ratio of 4.88 and a beta of 0.89. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.44 and a quick ratio of 1.44. Acadia Healthcare has a one year low of $11.43 and a one year high of $42.85.

Acadia Healthcare (NASDAQ:ACHC) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.04. The firm had revenue of $821.46 million during the quarter, compared to analyst estimates of $800.10 million. Acadia Healthcare had a return on equity of 7.66% and a net margin of 3.29%.The company’s revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.64 earnings per share. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS. Analysts expect that Acadia Healthcare will post 3.38 EPS for the current fiscal year.

Institutional Trading of Acadia Healthcare

A number of institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP boosted its position in Acadia Healthcare by 24.9% in the fourth quarter. Wellington Management Group LLP now owns 11,774,308 shares of the company’s stock worth $167,077,000 after purchasing an additional 2,350,760 shares during the last quarter. Vanguard Group Inc. increased its position in Acadia Healthcare by 7.8% in the third quarter. Vanguard Group Inc. now owns 9,417,045 shares of the company’s stock worth $233,166,000 after buying an additional 681,278 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Acadia Healthcare by 417.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,728,613 shares of the company’s stock worth $67,099,000 after buying an additional 3,815,471 shares during the period. Abrams Bison Investments LLC lifted its position in shares of Acadia Healthcare by 22.3% during the 3rd quarter. Abrams Bison Investments LLC now owns 4,380,000 shares of the company’s stock valued at $108,449,000 after buying an additional 800,000 shares in the last quarter. Finally, UBS Group AG grew its stake in shares of Acadia Healthcare by 8.8% during the 3rd quarter. UBS Group AG now owns 4,336,698 shares of the company’s stock valued at $107,377,000 after acquiring an additional 350,484 shares during the period.

More Acadia Healthcare News

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Q4 revenue beat and modest EPS beat — Acadia reported Q4 revenue of $821.5M vs. ~$800M expected and EPS of $0.07 vs. $0.03 consensus, driven by higher admissions and patient days. Article Title
• Positive Sentiment: Volume/capacity expansion cited as a growth driver — company commentary and press coverage highlight same‑facility revenue growth and capacity increases; these operational gains helped spark a sizable intraday rally. Article Title
• Positive Sentiment: Q1 2026 guidance well above consensus — Acadia guided Q1 EPS to $0.25–$0.30 vs. consensus ~$0.11, signaling near‑term improving execution and supporting the stock move. Article Title
• Positive Sentiment: Analyst support — TD Cowen reiterated a Buy and raised the price target to $24, citing improving execution and embedded EBITDA growth under management changes. Article Title
• Neutral Sentiment: Earnings materials and call transcript available — the full press release and Q4 earnings call transcript provide detail on volumes, payor mix and cost trends for investors doing deeper due diligence. Article Title
• Negative Sentiment: FY 2026 EPS guidance below Street — Acadia trimmed FY EPS to $1.30–$1.55 vs. consensus ~ $1.75, introducing downside risk to full‑year earnings expectations. Article Title
• Negative Sentiment: Profit collapse year‑over‑year — operating results show EPS down sharply from prior year (Zacks cites ~89% YoY plunge), indicating margin pressure despite revenue growth. Article Title
• Negative Sentiment: Very high short interest — recent filings show ~35.9% of shares sold short (short‑interest ratio ~7.3 days), which raises downside pressure but also creates potential for volatile squeezes. (Company short‑interest disclosures)

About Acadia Healthcare

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.